Allogene Therapeutics Inc... (ALLO)

1.80

-0.15 (-7.69%)

At close: Mar 03, 2025, 3:59 PM

1.79

-0.56%

After-hours: Mar 03, 2025, 07:09 PM EST

Allogene Therapeutics Cash Flow Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Net Income	-327.26M	-332.63M	-257M	-250.22M	-184.59M	-211.5M	-24K
Depreciation & Amortization	14.2M	14.29M	10.45M	7.59M	5.03M	1.5M	n/a
Stock-Based Compensation	65.95M	83.6M	80.82M	65.26M	46.06M	18.57M	n/a
Other Working Capital	-7.8M	-1.16M	-31.32M	53.31M	-5.89M	3.3M	24K
Other Non-Cash Items	24.69M	2.43M	2.61M	3.96M	3.36M	134.81M	n/a
Deferred Income Tax	n/a	8.08M	10.4M	4.4M	-331K	-117K	n/a
Change in Working Capital	-15.3M	3.71M	-32.09M	53.92M	-6.88M	12.1M	24K
Operating Cash Flow	-237.73M	-220.52M	-184.81M	-115.09M	-137.35M	-44.65M	n/a
Capital Expenditures	-1.52M	-5.19M	-21.45M	-65.96M	-50.79M	-3.23M	n/a
Acquisitions	n/a	-111.35M	-17.71M	439.17M	-5.08M	n/a	n/a
Purchase of Investments	-438.63M	-248.11M	-525.58M	-1.04B	-252.63M	-649.31M	n/a
Sales Maturities Of Investments	603.43M	359.46M	728.39M	598.43M	472.58M	21.84M	n/a
Other Investing Acitivies	n/a	111.35M	185.1M	-439.17M	214.88M	-2.1M	n/a
Investing Cash Flow	163.29M	106.16M	163.66M	-505.12M	164.08M	-632.8M	n/a
Debt Repayment	n/a	n/a	n/a	n/a	n/a	116.84M	n/a
Common Stock Repurchased	n/a	2.46M	3.62M	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	4.58M	2.95M	11.96M	11.66M	4.74M	953.62M	n/a
Financial Cash Flow	95.69M	2.95M	11.96M	633.59M	58.96M	771.18M	n/a
Net Cash Flow	21.25M	-111.41M	-9.19M	13.38M	85.69M	93.73M	n/a
Free Cash Flow	-239.25M	-225.71M	-206.26M	-181.05M	-188.14M	-47.89M	n/a